Andreadakis, J., Wilkins, O., Shkembi, A., Wu, A., Basile, J., Krzeczowska, A., Thalberg, A., Linderbeck, L., Zapata, N., Silbert, S., O'Driscoll, M., Renteria, A., Albitar, M., Williams, L., Salemi, J., Alman, A., Martin, T., Swoboda, D., Rivero, G. (2025). Real-world validation of the molecular prognostic risk signature in acute myeloid leukemia treated with hypomethylating agents plus BCL-2 inhibitor.. Blood. https://doi.org/10.1182/blood-2025-3413